LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 15

Search options

  1. Article ; Online: The Effect of JAK Inhibitors on Patient-Reported Outcomes in Psoriatic Arthritis.

    Tsiogkas, Sotirios G / Perricone, Carlo / Bogdanos, Dimitrios P

    Mediterranean journal of rheumatology

    2024  Volume 35, Issue Suppl 1, Page(s) 20–26

    Abstract: Objective: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin of patients with psoriasis. In this review we aimed to summarise the available evidence regarding the effect of Janus kinase inhibitors (JAKi) on ... ...

    Abstract Objective: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin of patients with psoriasis. In this review we aimed to summarise the available evidence regarding the effect of Janus kinase inhibitors (JAKi) on patient-reported outcomes (PROs) when used for the management of PsA.
    Methods: We utilised a narrative review approach as we searched the available literature for articles to be included in our study.
    Results: JAKi have been found to be effective in inducing better PRO responses compared to placebo. These findings have been consistent across various patient populations, including those with active PsA, those with an inadequate response to conventional therapies, and those with comorbidities. The evidence supporting the benefits of JAKi on PROs in PsA is compelling, demonstrating consistent improvements in pain, physical function, fatigue, and quality of life.
    Conclusion: Numerous studies have demonstrated the the efficacy of JAKi in improving PROs in patients with PsA.
    Language English
    Publishing date 2024-03-30
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 3019943-8
    ISSN 2529-198X ; 2459-3516
    ISSN (online) 2529-198X
    ISSN 2459-3516
    DOI 10.31138/mjr.171223.tej
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Artificial Intelligence and Prediction of Response to Biologics in Psoriatic Disease Using Immunophenotype Data: A Mini Review.

    Tsiogkas, Sotirios G / Dvir, Yoad M / Shoenfeld, Yehuda / Bogdanos, Dimitrios P

    The Israel Medical Association journal : IMAJ

    2024  Volume 26, Issue 2, Page(s) 114–119

    MeSH term(s) Humans ; Biological Products/pharmacology ; Biological Products/therapeutic use ; Artificial Intelligence ; Arthritis, Psoriatic ; Psoriasis/drug therapy
    Chemical Substances Biological Products
    Language English
    Publishing date 2024-02-29
    Publishing country Israel
    Document type Review ; Journal Article
    ZDB-ID 2008291-5
    ISSN 1565-1088 ; 0021-2180
    ISSN 1565-1088 ; 0021-2180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5470: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis.

    Tsiogkas, Sotirios G / Karamitrou, Eleni K / Grammatikopoulou, Maria G / Zafiriou, Efterpi / Bogdanos, Dimitrios P

    Current medical research and opinion

    2024  Volume 40, Issue 2, Page(s) 155–163

    Abstract: Objectives: Psoriasis of the scalp is challenging to manage. The only approved oral tyrosine kinase 2 and phosphodiesterase 4 inhibitors for psoriasis are deucravacitinib and apremilast. The aim of this study was to explore their efficacy for scalp ... ...

    Abstract Objectives: Psoriasis of the scalp is challenging to manage. The only approved oral tyrosine kinase 2 and phosphodiesterase 4 inhibitors for psoriasis are deucravacitinib and apremilast. The aim of this study was to explore their efficacy for scalp psoriasis utilizing data from randomized controlled trials.
    Methods: We searched Medline, Scopus, Web of Science, CENTRAL, and ClinicalTrials.gov up to August 4, 2023. To determine risk of bias, the revised Risk of Bias assessment tool 2.0 was used. Inverse variance random effects meta-analyses were executed. Heterogeneity was assessed utilizing Q and I
    Results: Ten RCTs fulfilled inclusion criteria. Both apremilast (RR = 2.41, 95% CI = 2.08-2.79, Tau
    Conclusions: Apremilast and deucravacitinib are effective for scalp psoriasis. Deucravacitinib may be more efficient in clearing the scalp.
    MeSH term(s) Humans ; Phosphodiesterase 4 Inhibitors/therapeutic use ; Cyclic Nucleotide Phosphodiesterases, Type 4/therapeutic use ; TYK2 Kinase/therapeutic use ; Scalp ; Psoriasis/drug therapy ; Tyrosine/therapeutic use ; Severity of Illness Index ; Treatment Outcome ; Randomized Controlled Trials as Topic ; Thalidomide/analogs & derivatives
    Chemical Substances apremilast (UP7QBP99PN) ; Phosphodiesterase 4 Inhibitors ; Cyclic Nucleotide Phosphodiesterases, Type 4 (EC 3.1.4.17) ; TYK2 Kinase (EC 2.7.10.2) ; Tyrosine (42HK56048U) ; Thalidomide (4Z8R6ORS6L)
    Language English
    Publishing date 2024-01-24
    Publishing country England
    Document type Meta-Analysis ; Systematic Review ; Journal Article
    ZDB-ID 80296-7
    ISSN 1473-4877 ; 0300-7995
    ISSN (online) 1473-4877
    ISSN 0300-7995
    DOI 10.1080/03007995.2023.2288280
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 955: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Proteomics in Patients with Fibromyalgia Syndrome: A Systematic Review of Observational Studies.

    Gkouvi, Arriana / Tsiogkas, Sotirios G / Bogdanos, Dimitrios P / Gika, Helen / Goulis, Dimitrios G / Grammatikopoulou, Maria G

    Current pain and headache reports

    2024  

    Abstract: Purpose of review: Fibromyalgia syndrome (FMS) is a disease of unknown pathophysiology, with the diagnosis being based on a set of clinical criteria. Proteomic analysis can provide significant biological information for the pathophysiology of the ... ...

    Abstract Purpose of review: Fibromyalgia syndrome (FMS) is a disease of unknown pathophysiology, with the diagnosis being based on a set of clinical criteria. Proteomic analysis can provide significant biological information for the pathophysiology of the disease but may also reveal biomarkers for diagnosis or therapeutic targets. The present systematic review aims to synthesize the evidence regarding the proteome of adult patients with FMS using data from observational studies.
    Recent findings: An extensive literature search was conducted in MEDLINE/PubMed, CENTRAL, and clinicaltrials.gov from inception until November 2022. The study protocol was published in OSF. Two independent reviewers evaluated the studies and extracted data. The quality of studies was assessed using the modified Newcastle-Ottawa scale adjusted for proteomic research. Ten studies fulfilled the protocol criteria, identifying 3328 proteins, 145 of which were differentially expressed among patients with FMS against controls. The proteins were identified in plasma, serum, cerebrospinal fluid, and saliva samples. The control groups included healthy individuals and patients with pain (inflammatory and non-inflammatory). The most important proteins identified involved transferrin, α-, β-, and γ-fibrinogen chains, profilin-1, transaldolase, PGAM1, apolipoprotein-C3, complement C4A and C1QC, immunoglobin parts, and acute phase reactants. Weak correlations were observed between proteins and pain sensation, or quality of life scales, apart from the association of transferrin and a2-macroglobulin with moderate-to-severe pain sensation. The quality of included studies was moderate-to-good. FMS appears to be related to protein dysregulation in the complement and coagulation cascades and the metabolism of iron. Several proteins may be dysregulated due to the excessive oxidative stress response.
    Language English
    Publishing date 2024-04-23
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2055062-5
    ISSN 1534-3081 ; 1531-3433
    ISSN (online) 1534-3081
    ISSN 1531-3433
    DOI 10.1007/s11916-024-01244-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5477: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

    Simopoulou, Theodora / Tsiogkas, Sotirios G / Zafiriou, Efterpi / Bogdanos, Dimitrios P

    Drugs of today (Barcelona, Spain : 1998)

    2023  Volume 59, Issue 3, Page(s) 135–167

    Abstract: In recent years, the role of interleukin-17 (IL-17) in orchestrating and manipulating proinflammatory immune responses has received special attention. It has become apparent from murine studies and clinical trials that due to its inhibitory effect on ... ...

    Abstract In recent years, the role of interleukin-17 (IL-17) in orchestrating and manipulating proinflammatory immune responses has received special attention. It has become apparent from murine studies and clinical trials that due to its inhibitory effect on immunoregulation and its stimulatory action on promoting proinflammatory responses, IL-17 is an ideal cytokine to target for drug development, in order to cease its induction or eliminate IL-17-producing cells of any kind. Several monoclonal antibodies have been developed and tested as potent inhibitors of IL-17 in various inflammatory diseases. This review summarizes data from relevant clinical trials on recent developments of the application of inhibitors of IL-17 in psoriasis and psoriatic arthritis, namely secukinumab, ixekizumab, bimekizumab and brodalumab.
    MeSH term(s) Humans ; Animals ; Mice ; Arthritis, Psoriatic/drug therapy ; Interleukin-17 ; Psoriasis/drug therapy
    Chemical Substances secukinumab (DLG4EML025) ; ixekizumab (BTY153760O) ; brodalumab (6ZA31Y954Z) ; bimekizumab (09495UIM6V) ; Interleukin-17
    Language English
    Publishing date 2023-02-27
    Publishing country Spain
    Document type Review ; Journal Article
    ISSN 1699-3993
    ISSN 1699-3993
    DOI 10.1358/dot.2023.59.3.3419557
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: CD32 (FcγRIIB) expression is low on CD21

    Kourkouni, Evangeli / Tsiogkas, Sotirios G / Mavropoulos, Athanasios / Simopoulou, Theodora / Katsiari, Christina G / Bogdanos, Dimitrios P / Sakkas, Lazaros I

    Clinical immunology (Orlando, Fla.)

    2024  Volume 262, Page(s) 110195

    Abstract: ... ...

    Abstract CD21
    MeSH term(s) Humans ; Leukocytes, Mononuclear ; Scleroderma, Systemic ; Lung Diseases, Interstitial ; DNA Topoisomerases, Type I ; Nuclear Proteins ; Skin Ulcer
    Chemical Substances Scl 70 antigen, human ; DNA Topoisomerases, Type I (EC 5.99.1.2) ; Nuclear Proteins
    Language English
    Publishing date 2024-03-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1459903-x
    ISSN 1521-7035 ; 1521-6616
    ISSN (online) 1521-7035
    ISSN 1521-6616
    DOI 10.1016/j.clim.2024.110195
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 880: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Cannabidiol Mediates

    Tsiogkas, Sotirios G / Apostolopoulou, Konstantina / Papagianni, Evangelia D / Mavropoulos, Athanasios / Dardiotis, Efthimios / Zafiriou, Efterpi / Bogdanos, Dimitrios P

    Cannabis and cannabinoid research

    2024  Volume 9, Issue 1, Page(s) 134–146

    Abstract: Background: ...

    Abstract Background:
    MeSH term(s) Humans ; Cytokines/metabolism ; Interleukin-17/metabolism ; Cannabidiol/pharmacology ; Psoriasis/drug therapy ; Psoriasis/metabolism ; Interleukins ; Interferon-gamma
    Chemical Substances Cytokines ; Interleukin-17 ; Cannabidiol (19GBJ60SN5) ; Interleukins ; Interferon-gamma (82115-62-6)
    Language English
    Publishing date 2024-01-05
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2867624-5
    ISSN 2378-8763 ; 2578-5125
    ISSN (online) 2378-8763
    ISSN 2578-5125
    DOI 10.1089/can.2023.0237
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Risk of multiple sclerosis in patients with psoriasis receiving anti-IL-17 agents: A case-based review.

    Tsiogkas, Sotirios G / Tsimourtou, Vaia / Chaidaki, Kleoniki / Dardiotis, Efthymios / Roussaki-Schulze, Angeliki Victoria / Bogdanos, Dimitrios P / Zafiriou, Efterpi

    The Journal of dermatology

    2024  

    Abstract: Biologics approved for psoriasis exhibit favorable safety profiles, and serious adverse events have rarely been reported. In this report, we present the case of a patient treated with ixekizumab, an anti-interleukin (IL)-17 agent, who 8 months later ... ...

    Abstract Biologics approved for psoriasis exhibit favorable safety profiles, and serious adverse events have rarely been reported. In this report, we present the case of a patient treated with ixekizumab, an anti-interleukin (IL)-17 agent, who 8 months later developed multiple sclerosis (MS). We also review the available literature regarding the use of anti-IL-17 agents in the context of psoriasis and pre-existing or new-onset demyelination. Eight case reports were evaluated as relevant and are presented in our report. In most of the cases secukinumab or ixekizumab administration adequately controlled both skin and pre-existing neurological clinical manifestations. However, there has been a report of MS exacerbation under secukinumab treatment and the occurrence of myelitis in a patient receiving ixekizumab. While the anti-IL-17-biologic-mediated induction of inflammatory events in the central nervous system has not been proven and a causal relationship is lacking, such a probability should be considered in extremely rare cases.
    Language English
    Publishing date 2024-02-12
    Publishing country England
    Document type Journal Article
    ZDB-ID 800103-0
    ISSN 1346-8138 ; 0385-2407
    ISSN (online) 1346-8138
    ISSN 0385-2407
    DOI 10.1111/1346-8138.17143
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1950: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: A sharp decrease of Th17, CXCR3+-Th17, and Th17.1 in peripheral blood is associated with an early anti-IL-17-mediated clinical remission in psoriasis.

    Tsiogkas, Sotirios G / Mavropoulos, Athanasios / Dardiotis, Efthimios / Zafiriou, Efterpi / Bogdanos, Dimitrios P

    Clinical and experimental immunology

    2022  Volume 210, Issue 1, Page(s) 79–89

    Abstract: Psoriasis-an immune-mediated skin disease-implicates in its pathophysiology by circulating pro-inflammatory cell populations, cytokines, and their interactions with the epidermis. The direct effect of approved anti-interleukin- (IL-)17A and anti-IL-17R ... ...

    Abstract Psoriasis-an immune-mediated skin disease-implicates in its pathophysiology by circulating pro-inflammatory cell populations, cytokines, and their interactions with the epidermis. The direct effect of approved anti-interleukin- (IL-)17A and anti-IL-17R biologic therapy on immunophenotyping of peripheral blood mononuclear lymphocytes' (PBMCs) relative sub-population frequencies in psoriasis patients has not yet been described. Using multiparameter flow cytometry we examined T-cell subpopulations characterized by CCR6, CCR4, and CXCR3 chemokine receptor surface expression at baseline and after initiation of biologic therapy in PBMCs collected from 30 psoriasis patients. Increased CD3+CD4+CXCR3+, CD3+CD4+CCR6+CCR4+CXCR3+(CXCR3+-Th17), and CD3+CD4+CCR6+CCR4-CXCR3+(Th17.1) cell populations were observed in patients with psoriasis in comparison to healthy individuals (n = 10). IL-17 therapeutic blockade decreased CD3+CD4+CCR6+, CD3+CD4+CXCR3+, CD3+CD4+CCR6-CXCR3+(Th1), CD3+CD4+CCR6+CCR4+(Th17), CD3+CD4+CCR6+CCR4+CXCR3+(CXCR3+-Th17), and CD3+CD4+CCR6+CCR4-CXCR3+(Th17.1) cell populations in responding psoriasis patients. Moreover, CD3+CD4-CCR6+, CD3+CD4-CXCR3+, CD3+CD4-CCR6+CCR4+(Tc17), and CD3+CD4-CCR6-CXCR3+(Tc1) percentages were also inhibited. Modulation of the same cell sub-populations was also assessed in patients treated with methotrexate (n = 4), apremilast (n = 4), and anti-IL-23 biologic treatment (n = 4). In our study, the levels and functional capacity of peripheral pro-inflammatory Th1, Th17, and additional CCR6+T cell sub-gated populations from psoriasis patients that were treated with anti-IL-17 or anti-IL-17R targeted biologic therapy were explored for the first time. Our data clearly demonstrate that early anti-IL-17 mediated clinical remission is accompanied by a significant decrease of Th1, Th17, CXCR3+-Th17, and Th17.1 cells.
    MeSH term(s) Humans ; Leukocytes, Mononuclear/metabolism ; Methotrexate ; Th17 Cells/metabolism ; Psoriasis/drug therapy ; Psoriasis/metabolism ; Interleukins/metabolism ; Cytokines/metabolism ; Biological Products ; Receptors, CXCR3
    Chemical Substances Methotrexate (YL5FZ2Y5U1) ; Interleukins ; Cytokines ; Biological Products ; CXCR3 protein, human ; Receptors, CXCR3
    Language English
    Publishing date 2022-08-17
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218531-3
    ISSN 1365-2249 ; 0009-9104 ; 0964-2536
    ISSN (online) 1365-2249
    ISSN 0009-9104 ; 0964-2536
    DOI 10.1093/cei/uxac069
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 337: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis.

    Tsiogkas, Sotirios G / Grammatikopoulou, Maria G / Kontouli, Katerina-Maria / Minopoulou, Ioanna / Goulis, Dimitrios D / Zafiriou, Efterpi / Bogdanos, Dimitrios P / Patsatsi, Aikaterini

    Expert review of clinical immunology

    2023  Volume 19, Issue 12, Page(s) 1485–1498

    Abstract: Background: Palmoplantar psoriasis (PP) represents a localized type of disease. While controversy over its' classification exists, a hyperkeratotic type, a pustular type and palmoplantar pustulosis (PPP) have been recognized. PP management is regularly ... ...

    Abstract Background: Palmoplantar psoriasis (PP) represents a localized type of disease. While controversy over its' classification exists, a hyperkeratotic type, a pustular type and palmoplantar pustulosis (PPP) have been recognized. PP management is regularly supported by biologic agents. Our study aimed to review and synthesize available data regarding the efficacy of approved biologics for PP and PPP.
    Research design and methods: A literature search was conducted in PubMed, CENTRAL, Scopus, and ClinicalTrilas.gov. Utilizing random-effects inverse-variance frequentist network meta-analyses (NMAs), we ranked interventions. The proportion of participants with cleared skin was the primary outcome. Fifty and 75% improvement in palmoplantar psoriasis area severity index (PPASI) were also explored (PPASI50, PPASI75).
    Results: In total, 15 randomized controlled trials (RCTs) exploring the efficacy of on-label adalimumab, bimekizumab, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, and ustekinumab were included. Data for PP were synthesized. Every biologic agent examined, except from infliximab, outperformed placebo. On-label secukinumab exhibited the highest probability of inducing complete resolution. Ixekizumab and infliximab ranked best on inducing PPASI50 and PPASI75. Our review supports that guselkumab is effective for PPP.
    Conclusions: Secukinumab, ixekizumab and infliximab are effective for PP. Research is warranted to produce evidence about the efficacy of biologics in PP and PPP.
    MeSH term(s) Humans ; Infliximab/therapeutic use ; Network Meta-Analysis ; Biological Factors/therapeutic use ; Psoriasis/drug therapy ; Biological Products/therapeutic use ; Severity of Illness Index ; Treatment Outcome
    Chemical Substances Infliximab (B72HH48FLU) ; Biological Factors ; Biological Products
    Language English
    Publishing date 2023-11-06
    Publishing country England
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Review
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1080/1744666X.2023.2272049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6661: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top